Clearmind reports MEAI intranasal study progress
- Clearmind reported successful formulation-feasibility results for intranasal delivery of MEAI.
- The study showed MEAI can be stably incorporated into a fully soluble intranasal solution.
- The company said the results support continued development of intranasal MEAI for alcohol use disorder.
Clearmind (NASDAQ:CMND) reported successful formulation-feasibility results for intranasal delivery of MEAI, its lead candidate initially aimed at treating alcohol use disorder.
The study tested whether MEAI could be delivered through the nose as an additional route of administration.
Clearmind said the study showed MEAI can be stably incorporated into an intranasal formulation as a fully soluble solution.
The company said the formulation results support continued development of this additional delivery route for MEAI, while the initial target remains alcohol use disorder.
Clearmind said the intranasal approach could become another route for MEAI development.
The company’s broader work is focused on developing psychedelic-derived therapeutics for alcohol use disorder and other conditions.
Recent company updates have centered on MEAI development, formulation work, intellectual property, and potential new administration routes for its treatment pipeline.
